Project Grant R43HL167472
Award Date
9/17/24
Completion Date
3/31/25
Dollars Obligated
$270K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30308, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, awarded a $863,328 Project Grant to Aquillius Corp to develop a wearable graphene respiratory sensor for early detection and monitoring of asthma. The sensor is intended to provide real-time continuous monitoring and measurement of pulmonary functions, particularly for children, to improve asthma diagnosis, treatment, and patient care. The Phase I feasibility studies will focus on...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,107,276 to Lasarrus Clinic And Research Center Inc. to develop a mobile health system for remote monitoring of patients with Chronic Obstructive Pulmonary Disease (COPD). The project aims to enhance patient adherence to remote monitoring and early symptom recognition, in order to reduce COPD readmissions and healthcare costs. The system utilizes a wearable...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will evaluate the use of mobile devices to extract vital signs to monitor patients with asthma. The $459,127 award to M5 Enterprise, LLC (doing business as Emedical Sentry) aims to improve the detection and management of asthma attacks through remote patient monitoring. The goal is to enhance telehealth by incorporating video-based vital sign...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $300,000 to develop a hand-held smart sensor system that can noninvasively detect exhaled volatile organic compound (VOC) biomarkers for predicting pulmonary exacerbations in children with cystic fibrosis. The goal is to leverage machine learning to identify a breath-based biosignature for pulmonary exacerbations, design and test...
This Project Grant award of $1,331,984.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to develop new lung quantitative ultrasound (LQUS) metrics for monitoring pulmonary edema due to heart failure and idiopathic pulmonary fibrosis. The primary awardee, North Carolina State University, will work to mitigate chest-wall effects, optimize data acquisition, and apply LQUS methods in human patients with heart failure and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $842,408 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Inspire RX LLC, a start-up company based in Ann Arbor, Michigan. The goal of this 18-month project is to refine and further evaluate Inspire RX's "Aerosolve Biohelmet", a personal negative pressure device capable of preventing the spread of aerosolized pathogens while enabling non-invasive oxygen therapies for patients with highly...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research aims to develop novel physiological markers of high-risk labored breathing to provide advance warning of respiratory failure. The $807,067 award to the Rector & Visitors of the University of Virginia will fund a 5-year study to quantify respiratory kinematics using a new wearable sensor technology called ARK (Analysis of Respiratory Kinematics). The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $477,191 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Phrase Health, Inc., a small disadvantaged business located in Philadelphia, PA. The purpose of this 22-month project is to develop a library of "out of the box" quality improvement (QI) templates focused on select lung diseases, including asthma, bronchiolitis, and COPD. The project will involve translating existing QI project templates from...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,530 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Spinhance LLC, a for-profit limited liability company located in Rydal, Pennsylvania. The grant aims to design, build, and evaluate a novel cardiopulmonary imaging device for continuous administration of the magnetic resonance imaging (MRI) contrast agent hyperpolarized xenon-129. This system is intended to support a new paradigm for...